Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 149-154

  Isgrò, Antonella ^a   Gaziev, Javid ^a   Sodani, Pietro ^a   Lucarelli, Guido ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

alternative donors; haploidentical transplant; HSCT; thalassemia

Indexed keywords

AZATHIOPRINE; BUSULFAN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; THIOTEPA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BETA THALASSEMIA; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL EVALUATION; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG TOLERABILITY; GENE THERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC SYSTEM; HEPATOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LIVER FIBROSIS; LOW DRUG DOSE; NATURAL KILLER CELL; RISK FACTOR;

EID: 77955906239     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05543.x     Document Type: Conference Paper

References (25)

1. Slavin, S., R. Or, G Cividalli, et al. 1988. Bone marrow transplantation in thalassemia with prevention of graft-vs. host disease. In Birth Defects: Original Article Series. Thalassemia: Pathophysiology and Management, Vol.23, Part 5B. Fucharoen S., P.T. Rowley & N.W. Paul, Eds.: 313-316. Alan R Liss. NY, USA.
2. Parkman, R., J. Rappeport, R. Geha, et al. 1978. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N. Engl. J. Med. 298: 921-927.
3. Kapoor, N., D. Kirkpatrick, J. Oleske, et al. 1981. Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 57: 692-696.
4. Hobbs, J.R., K. Hugh-Jones, P.J. Shaw, et al. 1986. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant. 1: 201-208. (Pubitemid 18048962)
5. Thomas, E.D., C.D. Buckner, R. Storb, et al. 1972. Aplastic anaemia treated by marrow transplantation. Lancet 1: 284-289.
6. Storb, R., R.E. Champlin. 1991. Bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 8: 69-72.
7. Santos,G.W., L.L. Sensenbrenner,P.J.Burke, et al. 1971.Marrow transplantation in man following cyclophosphamide. Transplant. Proc. 3: 400-404.
8. Tutschka, P.J., G.J. Elfenbein, L.L. Sensenbrenner, et al. 1980. Preparative regimens for marrow transplantation in acute leukemia and aplastic anemia. Baltimore experience. Am. J. Ped. Hematol. Oncol. 2: 363-370.
9. Santos, G.W., P.J. Tutschka, R. Brookmeyer, et al. 1983.Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 309: 1347-1353.
10. Appelbaum, F.R., R. Storb, R.E. Ramberg, et al. 1984. Allogeneic marrow transplantation in the treatment of preleukemia. Ann. Intern. Med. 100: 689-693.
11. Tutschka, P.J., E.A.Copelan, N.Kapoor 1989. Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneicmarrowtransplantation. Transplant Proc. 21: 2952-2954.
12. Tutschka, P.J., E.A. Copelan, N. Kapoor, et al. 1991. Allogeneic bone marrow transplantation for leukemia using chemotherapy as conditioning. Six-year results of a single institution trial. Transplant Proc. 23: 1709-1710.
13. Floersheim, G.L. & L.A. Elson. 1961. Restoration of hematopoiesis following a lethal dose of dimethylmyleran by isologic bone marrow transplantation in mice. Experiments on modification of intolerance to homologous bone marrow by 6-mercaptopurine, amino-chlorambucil and cortisone. Acta Haematol. 26: 233-245.
14. Lucarelli, G.,M.Galimberti, P. Polchi, et al. 1990. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322: 417-421.
15. Storb, R., P.L. Weiden, T.C. Graham, et al. 1977. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associatedwithDLAand abrogated by antithymocyte serum. Transplantation 24: 349-357.
16. Lucarelli, G., M. Galimberti, P. Polchi, et al. 1993. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N. Engl. J. Med. 329: 840-844.
17. Lucarelli, G., R. Clift, M. Galimberti, et al. 1996. Marrow transplantation for patientswith thalassemia: results inClass 3 patients. Blood 87: 2082-2088.
18. Lucarelli, G.,M. Andreani & E. Angelucci. 2002. The cure of thalassemia by bone marrow transplantation. Blood Rev. 16: 81-85.
19. Sodani, P., J. Gaziev, P. Polchi, et al. 2004. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 104: 1201-1203.
20. Lucarelli, G.,M.Galimberti, P. Polchi, et al. 1992. Bone marrow transplantation in adult thalassemia. Blood 80: 1603-1607.
21. Lucarelli, G., Clift RA, M. Galimberti, et al. 1999. Bone marrow transplantation in adult thalassemic patients. Blood 93: 1164-1167. (Pubitemid 29076130)
22. Gaziev, J., P. Sodani, P. Polchi, et al. 2005. Bone marrow transplantation in adults with thalassemia. Treatment and long-term follow-up. Ann. N.Y. Acad. Sci. 1054: 196-205.
23. Gaziev, D., M. Galimberti, G. Lucarelli, et al. 2000. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA nonidentical sibling or parent transplants. Bone Marrow Transplant. 25: 815-821.
24. Ruggeri, L., A. Mancusi, E. Burchielli, et al. 2008. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol. Dis. 40: 84-90.
25. Isgr̀ o, A., P. Sodani, M. Marziali, et al. 2007. Early T cell recovery of thymus-derived naïve T cells and NK cells in paediatrics patients afterT-cell depletedHLA-haploidentical stem cell transplantation for thalassemia [abstract]. Blood 110: 336.